368 completed, 20 unknown, 18 terminated, 13 withdrawn. 445 Phase 1, 84 Phase 2.
Follow Mosquito-Borne Diseases: new trials by email Literature Review of Mosquito-Borne Diseases trials Research Report on Mosquito-Borne Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina Faso PfSPZ-LARC2 Vaccine, PfSPZ Challenge, Normal Saline - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | Sanaria Inc. | 45 | 2027-03-01 | 2026-07-31 |
| Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant - Randomised Clinical Trial, Double Blind | Phase 1 | Not yet recruiting | VLP Therapeutics | 42 | 2027-01-04 | 2026-09-21 |
| Malaria CVD 36000; Gates INV090205 PfSPZ Challenge (NF54), Wearable Biosensor Devices, Placebo - Malaria (Plasmodium Falciparum) | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 32 | 2026-11-01 | 2026-09-09 |
| A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults Piperaquine, Artesunate-pyronaridine (Pyramax), Piperaquine and artesunate-pyronaridine (Pyramax) - Malaria | Phase 1 | Not yet recruiting | University of Oxford | 24 | 2026-11-01 | 2026-08-05 |
| Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years LYB014 low dose, LYB014 high dose, LYB017 low dose - Malaria Vaccine | Phase 1 | Not yet recruiting | Guangzhou Patronus Biotech Co., Ltd. | 72 | 2026-10-01 | 2026-10-22 |
| Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali. Cohort 1 low dose lotilaner with a high-fat meal, Cohort 1 low dose placebo with a high-fat meal, Cohort 2 high dose lotilaner in fasted state - Malaria | Phase 1 | Recruiting | Medicines for Malaria Venture | 75 | 2026-09-14 | 2026-09-24 |
| Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) PfSPZ Vaccine, PfSPZ Diluent, Normal Saline - Malaria | Phase 1 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-09-14 | 2026-09-16 | |
| Artemisia Annua Infusion for the Treatment of Asymptomatic Plasmodium Falciparum Infection Artemisia Annua Leaf, Centaurii herba - Asymptomatic P.Falciparum Malaria | Phase 1 | Not yet recruiting | Centre de Recherche Médicale de Lambaréné | 20 | 2026-09-01 | 2026-09-15 |
| Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in Rwanda MMV371, Placebo for MMV371 - Malaria (Plasmodium Falciparum), Malaria Falciparum | Phase 1 | Not yet recruiting | Medicines for Malaria Venture | 80 | 2026-09-01 | 2026-04-23 |
| Phase 1 Challenge Study Using rDEN2delta30-7169 to Evaluate Host-Pathogen Interactions in Primary, Homotypic, and Heterotypic Dengue Virus Infection rDEN2delta30-7169 - Healthy Volunteers, Dengue | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2026-08-07 | 2026-10-22 |
| First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults GSK4425689A SC, GSK4425689A IV, Placebo - Malaria, Falciparum | Phase 1 | Recruiting | GlaxoSmithKline | 40 | 2026-07-27 | 2026-10-05 |
| Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years Midazolam (MDZ), GSK3772701 - Malaria, Falciparum | Phase 1 | Completed | GlaxoSmithKline | 20 | 2026-06-26 | 2026-09-30 |
| A Challenge Study to Assess the Blood-stage Efficacy of Full-length SUM-101 Malaria Vaccine Candidate SUM-101, CHMI, Verorab® - Malaria Fever | Phase 1 | Withdrawn | European Vaccine Initiative | 2026-03-20 | 2026-09-11 | |
| Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults Normal Saline (Placebo), PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8) - Malaria Falciparum | Phase 1 | Recruiting | Sanaria Inc. | 42 | 2026-03-12 | 2026-11-03 |
| A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine) R21, RH5.1, R78C - Malaria,Falciparum | Phase 1 | Active not recruiting | University of Oxford | 56 | 2025-09-15 | 2026-10-21 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax." Vivaxin vaccine manufactured by CT Vacinas/Cristália Laboratory, Placebo - Malaria Vivax | Phase 1 | Not yet recruiting | Federal University of Minas Gerais | 48 | 2025-09-01 | 2025-09-15 |
| A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers V4020 - Venezuelan Equine Encephalitis, Venezuelan Equine Encephalitis Virus Infection | Phase 1 | Not yet recruiting | Medigen, Inc. | 39 | 2025-08-15 | 2025-07-28 |
| Safety and Immunogenicity of SUM-101 Malaria Vaccine in Children and Infants Living in Burkina Faso SUM-101 - Malaria,Falciparum | Phase 1 | Completed | European Vaccine Initiative | 39 | 2025-08-01 | 2026-09-11 |
| First-in-Human PfSPZ-LARC2 Vaccination/CHMI PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9% - Malaria | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 22 | 2025-07-23 | 2026-08-17 |
| Controlled Human Malaria Infection by Mosquito Bites Using a Local Strain of Plasmodium Falciparum Controlled Human Malaria Infection - Malaria (Plasmodium Falciparum) | Phase 1 | Completed | Centre de Recherche Médicale de Lambaréné | 20 | 2025-07-18 | 2026-09-11 |
Showing 20 of 445. Sign in to see all of them.
Malaria (264) · Malaria, Falciparum (137) · Dengue (63) · Zika Virus Infection (21) · Malaria, Vivax (18) · Severe Dengue (16) · Virus Diseases (11) · Chikungunya Fever (10) · Parasitemia (9) · Infections (8) · Yellow Fever (8) · Flavivirus Infections (6) · Encephalomyelitis, Venezuelan Equine (5) · Parasitic Diseases (5) · West Nile Fever (5)
Vector Borne Diseases (442) · Infections (437) · Parasitic Diseases (320) · Protozoan Infections (319) · RNA Virus Infections (120) · Arbovirus Infections (117) · Virus Diseases (117) · Flaviviridae Infections (99) · Flavivirus Infections (95) · Hemorrhagic Fevers, Viral (73) · Malaria (59) · Pathological Conditions, Signs and Symptoms (17) · Central Nervous System Diseases (16) · Central Nervous System Infections (16)
Saline Solution (21) · Artemether, Lumefantrine Drug Combination (13) · Aluminum Hydroxide (12) · Primaquine (12) · Matrix-M (11) · Sodium Chloride (11) · Chloroquine (10) · Vaccines (9) · fanasil, pyrimethamine drug combination (8) · Rabies Vaccines (7) · artefenomel (7) · Artesunate (6) · piperaquine (6) · pyronaridine tetraphosphate, artesunate drug combination (6) · Lumefantrine (5)
National Institute of Allergy and Infectious Diseases (NIAID) (96) · University of Oxford (59) · Medicines for Malaria Venture (44) · U.S. Army Medical Research and Development Command (36) · Sanaria Inc. (23) · GlaxoSmithKline (14) · European Vaccine Initiative (6) · Novartis Pharmaceuticals (6) · Radboud University Medical Center (6) · African Malaria Network Trust (5) · London School of Hygiene and Tropical Medicine (5) · Swiss Tropical & Public Health Institute (4) · Valneva Austria GmbH (4) · Centre de Recherche Médicale de Lambaréné (3) · Emergent BioSolutions (3)
United States (171) · United Kingdom (58) · Australia (28) · Mali (28) · Burkina Faso (15) · Netherlands (13) · Tanzania (13) · Kenya (9) · Switzerland (9) · Thailand (9) · Gabon (8) · Germany (7) · The Gambia (6) · Uganda (6) · Belgium (5)
Anna Durbin, MD (29) · Patrick E Duffy, M.D. (8) · James McCarthy, Prof (6) · Adrian V Hill, DPhill FRCP (5) · Adrian VS Hill, D.Phil, FRCP (5) · Adrian V S Hill, MD (4) · Kristen Pierce, MD (4) · Ulrike Lorch, MD FRCA FFPM (4) · Adrian VS Hill (3) · Adrian VS Hill, MA, BM BCh, DPhil, DM (3) · Beth Kirkpatrick, MD (3) · Blaise Genton, MD PhD (3)
PMID 39787798, PMID 26383952, PMID 29217375, PMID 31932368, PMID 40245769, PMID 41014333, PMID 23526949, PMID 23899517, PMID 25211344, PMID 25801652, PMID 26292027, PMID 26292257, PMID 26424605, PMID 26458804, PMID 27695088, PMID 29389671, PMID 32239164, PMID 32275867, PMID 32394880, PMID 32572470, PMID 33717176, PMID 34179977, PMID 34194041, PMID 36682364, PMID 37971871, PMID 39324693, PMID 39708824, PMID 39805302, PMID 41176969, PMID 42253092, PMID 10190913, PMID 10501745, PMID 12663340, PMID 12742586, PMID 1313024, PMID 15069048, PMID 16904798, PMID 17075340, PMID 17428147, PMID 17925866, PMID 17940609, PMID 18060072, PMID 18190252, PMID 18213374, PMID 18231580, PMID 18253503, PMID 18270560, PMID 18337339, PMID 18378716, PMID 18419347
2019 (4), 2016 (3), 2014 (2), 2015 (2), U01CI000211 (2), 2017 (1), 2018 (1), 272201300017C-18-0-1 (1), 5UM1AI148684-04 (1), N01AI085346 (1), R01AI025136 (1), R01HL086488 (1), R01HL130763 (1), R01NS074409 (1), U01AI065683 (1)